07.05.2013 - Spanish diagnostics specialist STAT-Diagnostica has secured €17m in Series B financing.
The Barcelona-based specialist for decentralised testing said it will use the proceeds to complete development of the company’s Near Patient Testing diagnostic system Diagcore and clinical validation of its first products. Led by new investor Kurma Life Sciences Partners, the round also drew participation from new investors Idinvest, Boehringer Ingelheim Venture Fund, and, Caixa Capital Risc, the venture capital division of “la Caixa” as well as existing investors Ysios Capital and Axis.
Founded in 2010, STAT-Diagnostica develops Near Patient Testing systems that simplify and reduce time to results in the growing markets of molecular diagnostics and immunodiagnostics. Its Diagcore® platform enables multiplex qPCR and immundiagnostic analyses in 15 to 30 minutes per run. The company announced that its first testing cartridges will be directed at infectious disease detection, antibiotic resistance determination and detection of biomarkers in critically ill patients.
"The Series B financing is a significant milestone that will support our preparation for a European market launch in 2015,” said Jordi Carrera, CEO and co-founder of STAT-Diagnostica. As part of the Series B financing, Ysios Capital significantly increased its investment in STAT-Diagnostica to become the company’s largest shareholder.
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.
04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more